HPV vaccine acceptance among female Greek students

International Journal of Adolescent Medicine and Health

Volumn 22, Issue 2, 2010, Pages 271-273

  Bakogianni, Giannoula D ^a   Nikolakopoulos, Konstantinos M ^a   Nikolakopoulou, Nikoleta M ^a  

^a Patras Highest Institute of Education and Technology   (Greece)

Author keywords

Cervical cancer; Genital warts; HPV vaccine; Human papillomavirus

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; FEMALE; GREECE; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; PATIENT COMPLIANCE; STUDENT; VACCINATION;

EID: 77958174022     PISSN: 03340139     EISSN: None     Source Type: Journal    
DOI: 10.1515/IJAMH.2010.22.2.271     Document Type: Article

References (17)

1. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006; 61(6Suppl 1):S3-14.
2. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57(1):7-28.
3. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102(5 A):3-8. (Pubitemid 127695953)
4. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008;26(49):6244-57.
5. FUTURE II Study Group. Quadri-valent vaccine against human papillo-mavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915-27.
6. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al; Females United to Unilaterally Reduce Endo/ectocervical disease (FUTURE) I investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. NEJM 2007;356(19):192843.
7. Carter JJ, Madeleine MM, Shera K, Schwartz SM, Cushing-Haugen KL, Wipf GC, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001;61(5):1934-40. (Pubitemid 32692010)
8. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 2008;68(3):359-72.
9. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110(3 Suppl 1):S18-25.
10. Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 2008;7(10):1465-73.
11. Oh JK, Lim MK, Yun EH, Lee EH, Shin HR. Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: A nationwide interview survey. Vaccine 2009;Dec 14. [Epub ahead of print].
12. Garland SM. Prevention strategies against human papillomavirus in males. Gynecol Oncol 2010;Feb 4 [Epub ahead of print].
13. Kang HS, Moneyham L. Attitudes toward and intention to receive the human papilloma virus (HPV) vaccination and intention to use condoms among female Korean college students. Vaccine 2010;28(3):811-6.
14. Gottvall M, Larsson M, Höglund AT, Tydén T. High HPV vaccine acceptance despite low awareness among Swedish upper secondary school students. Eur J Contracept Reprod Health Care 2009;14(6):399-405.
15. Hsu YY, Fetzer SJ, Hsu KF, Chang YY, Huang CP, Chou CY. Intention to obtain human papillomavirus vaccination among Taiwanese undergraduate women. Sex Transm Dis 2009;36(11):686-92.
16. Wong WC, Fong B, Chan PK. Acceptance of human papillomavirus vaccination among first year female university students in Hong Kong. Sex Health 2009;6(4):264-71.
17. Do H, Seng P, Talbot J, Acorda E, Coronado GD, Taylor VM. HPV vaccine knowledge and beliefs among Cambodian American parents and community leaders. Asian Pac J Cancer Prev 2009;10(3):339-44.